Late reaction to ustekinumab infusion

Main Article Content

Marina Resener Morais *
Luana Pizarro Meneghello
Carina Flores de Oliveira
André Vicente Esteves Carvalho
(*) Corresponding Author:
Marina Resener Morais | mariresener@hotmail.com

Abstract

Psoriasis is a chronic inflammatory disease that directly affects the quality of life. Biologics are prescribed for patients unresponsive to conventional treatments and with severe forms of the disease. Ustekinumab is a fully human monoclonal antibody against the p40 subunit of interleukins 12/23 that is being used with satisfactory responses, achieving an improvement in the baseline Psoriasis Area and Severity Index of approximately 75% after 12 weeks of treatment. It has few side effects, including grater susceptibility to infections and development of reactions to the drug. Our report discusses a case of a cutaneous reaction to the use of ustekinumab in a 27 year-old male patient after the third dose of the medication. No similar case has been reported in the literature.

Downloads month by month

Downloads

Download data is not yet available.

Article Details